Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

Background: The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15–20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant appro...

Full description

Bibliographic Details
Main Authors: Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, Jacques Raphael, Phillip Blanchette, Abdullah Al-Humiqani, Monali Ray
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/15/17/4336